Highlights Net Earnings of $62.3 Million or $0.60 Per Diluted Share; Adjusted Net Earnings of $68.4 Million or $0.66 Per Diluted Share Core Net Interest Margin at 5.64% $384.8 Million of Organic Loan and Lease Growth in the Quarter Driven by $974.7 Million of Production Demand Deposits Increased $141.1 Million in the Quarter and are 25% of Total Deposits Core Deposits Increased $268.8 Million in the Quarter and are 52% of Total Deposits
LOS ANGELES, Oct.
BETHESDA, Md., October 21, 2014 and OSAKA, Japan, October 22, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) , a global biopharmaceutical company, and Takeda Pharmaceutical Company Limited (Takeda) today announced that on October 17, 2014, they entered into a global license, development, commercialization and supply agreement for AMITIZA ® (lubiprostone). Through this agreement, Takeda expanded its exclusive rights beyond the United States (U.S.) and Canada to further develop and commercialize AMITIZA in all global markets, except Japan and the People's Republic of China.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.